Patents by Inventor Bernhard Kölbl

Bernhard Kölbl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD TO PRODUCE A HIGHLY CONCENTRATED IMMUNOGLOBULIN PREPARATION FOR SUBCUTANEOUS USE
    Publication number: 20220153823
    Abstract: The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 19, 2022
    Inventors: Wolfgang Teschner, Harald Arno Butterwec, Azra Pljevljakovic, Theresa Friederik Bauer, Bernhard Koelbl, Hans-Peter Schwarz, Nebojsa Nikolic, Gerhard Poelsler, Johanna Kindermann
  • Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
    Patent number: 11242380
    Abstract: The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: February 8, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Wolfgang Teschner, Harald Arno Butterweck, Azra Pljevljakovic, Theresa Friederike Bauer, Bernhard Koelbl, Hans-Peter Schwarz, Nebojsa Nikolic, Gerhard Poelsler, Johanna Kindermann
  • METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD
    Publication number: 20210403504
    Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.
    Type: Application
    Filed: September 13, 2021
    Publication date: December 30, 2021
    Inventors: Leopold Bruckschwaiger, Sonja Svatos, Julia Nuernberger, Wolfgang Teschner, Harald Butterweck, Hans-Peter Schwarz, Thomas Gundinger, Bernhard Koelbl, Reinhard Grausenburger, Azra Pljevljakovic
  • Method to produce an immunoglobulin preparation with improved yield
    Patent number: 11136350
    Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 5, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Leopold Bruckschwaiger, Sonja Svatos, Julia Nuernberger, Wolfgang Teschner, Harald Butterweck, Hans-Peter Schwarz, Thomas Gundinger, Bernhard Koelbl, Reinhard Grausenburger, Azra Pljevljakovic
  • METHOD TO PRODUCE A HIGHLY CONCENTRATED IMMUNOGLOBULIN PREPARATION FOR SUBCUTANEOUS USE
    Publication number: 20190085064
    Abstract: The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.
    Type: Application
    Filed: November 13, 2018
    Publication date: March 21, 2019
    Inventors: Wolfgang Teschner, Harald Arno Butterweck, Azra Pljevljakovic, Theresa Friederike Bauer, Bernhard Koelbl, Hans-Peter Schwarz, Nebojsa Nikolic, Gerhard Poelsler, Johanna Kindermann
  • Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
    Patent number: 10125189
    Abstract: The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: November 13, 2018
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Wolfgang Teschner, Harald Arno Butterweck, Azra Pljevljakovic, Theresa Friederike Bauer, Bernhard Koelbl, Hans-Peter Schwarz, Nebojsa Nikolic, Gerhard Poelsler, Johanna Kindermann
  • STABILIZATION OF IMMUNOGLOBULINS THROUGH AQUEOUS FORMULATION WITH HISTIDINE AT WEAK ACIDIC TO NEUTRAL PH
    Publication number: 20180250401
    Abstract: The present invention provides, among other aspects, storage stable aqueous formulations of immunoglobulins with histidine at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing immunoglobulin compositions by formulating with histidine at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stable aqueous compositions of immunoglobulins at mildly acidic to neutral pH useful for parenteral administration.
    Type: Application
    Filed: December 29, 2017
    Publication date: September 6, 2018
    Inventors: Harald Arno Butterweck, Bernhard Kölbl, Lucia Gnauer, Wolfgang Teschner, Hans-Peter Schwarz
  • METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD
    Publication number: 20180118782
    Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.
    Type: Application
    Filed: November 8, 2017
    Publication date: May 3, 2018
    Inventors: Leopold Bruckschwaiger, Sonja Svatos, Julia Nuernberger, Wolfgang Teschner, Harald Butterweck, Hans-Peter Schwarz, Thomas Gundinger, Bernhard Koelbl, Reinhard Grausenburger, Azra Pljevljakovic
  • Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
    Patent number: 9855331
    Abstract: The present invention provides, among other aspects, storage stabile aqueous formulations of immunoglobulins with histidine at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing immunoglobulin compositions by formulating with histidine at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stabile aqueous compositions of immunoglobulins at mildly acidic to neutral pH useful for parenteral administration.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: January 2, 2018
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Harald Arno Butterweck, Bernhard Kölbl, Lucia Hofbauer, Wolfgang Teschner, Hans-Peter Schwarz
  • METHOD TO PRODUCE A HIGHLY CONCENTRATED IMMUNOGLOBULIN PREPARATION FOR SUBCUTANEOUS USE
    Publication number: 20160244512
    Abstract: The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.
    Type: Application
    Filed: September 16, 2015
    Publication date: August 25, 2016
    Inventors: Wolfgang Teschner, Harald Arno Butterweck, Azra Pljevljakovic, Theresa Friederike Bauer, Bernhard Koelbl, Hans-Peter Schwarz, Nebojsa Nikolic, Gerhard Poelsler, Johanna Kindermann
  • Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
    Patent number: 9403899
    Abstract: The present invention provides methods for reducing the amidolytic and anti-complement activity (ACA) content of an immunoglobulin composition through the use of cation exchange chromatography. In a specific embodiment, the invention provides methods for reducing the Factor XI and/or Factor XIa and/or ACA content of an immunoglobulin composition by collecting the leading portion of a cation exchange eluate. The present invention also provides immunoglobulin composition having reduced levels of amidolytic activity, Factor XI, and/or Factor XIa, and/or ACA content.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: August 2, 2016
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Wolfgang Teschner, Harald Arno Butterweck, Bernhard Kölbl, Lucia Hofbauer, Hans-Peter Schwarz
  • Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
    Patent number: 9175068
    Abstract: The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: November 3, 2015
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Wolfgang Teschner, Harald Arno Butterweck, Azra Pljevljakovic, Theresa Friederike Bauer, Bernhard Koelbl, Hans-Peter Schwarz, Nebojsa Nikolic, Gerhard Poelsler, Johanna Kindermann
  • METHOD TO PRODUCE AN IMMUNOGLOBULIN PREPARATION WITH IMPROVED YIELD
    Publication number: 20150133644
    Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.
    Type: Application
    Filed: June 19, 2014
    Publication date: May 14, 2015
    Inventors: Leopold Bruckschwaiger, Sonja Svatos, Julia Nuernberger, Wolfgang Teschner, Harald Arno Butterweck, Hans-Peter Schwarz, Thomas Gundinger, Bernhard Koelbl, Reinhard Grausenburger, Azra Pljevljakovic
  • Method to produce an immunoglobulin preparation with improved yield
    Patent number: 8993734
    Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: March 31, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Leopold Bruckschwaiger, Sonja Svatos, Julia Nürnberger, Wolfgang Teschner, Harald Arno Butterweck, Hans-Peter Schwarz, Thomas Gundinger, Bernhard Koelbl, Reinhard Grausenburger, Azra Pljevljakovic
  • Method to produce an immunoglobulin preparation with improved yield
    Patent number: 8940877
    Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: January 27, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Leopold Bruckschwaiger, Sonja Svatos, Julia Nuernberger, Wolfgang Teschner, Harald Arno Butterweck, Hans-Peter Schwarz, Thomas Gundinger, Bernhard Koelbl, Reinhard Grausenburger, Azra Pljevljakovic
  • STABILIZATION OF IMMUNOGLOBULINS THROUGH AQUEOUS FORMULATION WITH HISTIDINE AT WEAK ACIDIC TO NEUTRAL PH
    Publication number: 20140370000
    Abstract: The present invention provides, among other aspects, storage stabile aqueous formulations of immunoglobulins with histidine at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing immunoglobulin compositions by formulating with histidine at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stabile aqueous compositions of immunoglobulins at mildly acidic to neutral pH useful for parenteral administration.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 18, 2014
    Inventors: Harald Arno Butterweck, Bernhard Kölbl, Lucia Hofbauer, Wolfgang Teschner, Hans-Peter Schwarz
  • Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
    Patent number: 8795658
    Abstract: The present invention provides, among other aspects, storage stabile aqueous formulations of immunoglobulins with histidine at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing immunoglobulin compositions by formulating with histidine at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stabile aqueous compositions of immunoglobulins at mildly acidic to neutral pH useful for parenteral administration.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: August 5, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Harald Arno Butterweck, Bernhard Kölbl, Lucia Hofbauer, Wolfgang Teschner, Hans-Peter Schwarz
  • Method to produce an immunoglobulin preparation with improved yield
    Patent number: 8796430
    Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: August 5, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Leopold Bruckschwaiger, Sonja Svatos, Julia Nürnberger, Wolfgang Teschner, Harald Arno Butterweck, Hans-Peter Schwarz, Thomas Gundinger, Bernhard Koelbl, Reinhard Grausenburger, Azra Pljevljakovic
  • METHOD TO PRODUCE A HIGHLY CONCENTRATED IMMUNOGLOBULIN PREPARATION FOR SUBCUTANEOUS USE
    Publication number: 20140030252
    Abstract: The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.
    Type: Application
    Filed: July 24, 2013
    Publication date: January 30, 2014
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Wolfgang Teschner, Harald Arno Butterweck, Azra Pljevljakovic, Theresa Friederike Bauer, Bernhard Koelbl, Hans-Peter Schwarz, Nebojsa Nikolic, Gerhard Poelsler, Johanna Kindermann
  • Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
    Patent number: 8546548
    Abstract: The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: October 1, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Wolfgang Teschner, Harald Arno Butterweck, Azra Pljevljakovic, Theresa Friederike Bauer, Bernhard Koelbl, Hans-Peter Schwarz, Nebojsa Nikolic, Gerhard Poelsler, Johanna Kindermann